Tissue Therapies names CEO
Tuesday, 14 September, 2004
Tissue Therapies (ASX:TIS) has appointed Dr Stephen Mercer -- most recently managing director of Mercy Tissue Engineering -- as its new chief executive.
Dr Mercer is a registered medical practitioner, and has previously worked as general manager of Smith & Nephew Surgical and as a health industry specialist with IBM.
In recent laboratory trials, Tissue Therapies' VitroGro was shown to prompt higher rates of growth and migration of human skin cells than existing culture methods, which use foetal bovine serum or patient serum. VitroGro was also show to support the serum-free cultivation of corneal cells for the treatment of eye burns.
These results were presented by Queensland University of Technology researchers to the Australian and New Zealand Burns Association conference in Adelaide last week.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
